Safety, Tolerability, and Pharmacodynamics of GS ‐4224 in Healthy Participants and Participants With Chronic Hepatitis B
Liver International · 2026-06 · 46 (6)
DOI: 10.1111/liv.70695 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Liver International, online erschienen am 21.05.2026. Verfasst von Edward J Gane und 18 weiteren Autor:innen. Beteiligte Einrichtung: University of Auckland, Auckland, New Zealand. Hauptthemen laut MEDLINE: Antiviral Agents, Hepatitis B, Chronic. Die Arbeit nennt 44 Literaturangaben. Gefördert von: Gilead Sciences.
Abstract (Originalsprache)
Background & Aims This Phase 1a/b clinical study evaluated the safety, tolerability, pharmacodynamics (PD) response, and antiviral activity of GS‐4224, a first‐in‐class, programmed death‐ligand 1 (PD‐L1)‐binding orally bioavailable small molecule.
Methods
Participants were randomised to single and multiple ascending doses (S/MAD) of GS‐4224 or placebo‐to‐match (PTM). Healthy participants (HPs; 5 cohorts) received once‐daily GS‐4224 doses for 10 days, escalating from 20 to 1 000 mg. Participants with chronic hepatitis B (CHB; 5 cohorts) received once‐daily GS‐4224 100, 300, or 700 mg for 28 days. The primary objective was GS‐4224 safety and tolerability. PD markers in peripheral blood cells and the mean change in hepatitis B surface antigen (HBsAg) were measured.
Results
Overall, 60 HPs and 42 participants with CHB received GS‐4224, and 15 and 10 received PTM. There were no Grade ≥ 3 adverse events (AEs), serious AEs, or deaths among HPs. No participants with CHB experienced serious AEs or death. Grade ≥ 3 AEs occurred in 2 viremic participants (unrelated Grade 3 AE of acute exacerbation of hepatitis B [detected prior to GS‐4224 dosing] leading to study discontinuation; related Grade 3 AE of increased alanine aminotransferase). PD‐L1 receptor occupancy on cells with low PD‐L1 expression was dose‐dependent and peaked at 38% among HPs who received MAD of GS‐4224 1 000 mg and 35% among participants with CHB who received MAD of GS‐4224 700 mg. No changes in HBsAg levels were observed in participants with CHB who received GS‐4224.
Conclusions
In all participants, GS‐4224 was generally safe and well tolerated; however, no antiviral effect was detected at the doses evaluated.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- University of Auckland, Auckland, New Zealand.
- Division of Gastroenterology and Hepatology, Department of Medicine, Ditmanson Medical Foundation Chiayi Christian Hospital, Chiayi, Taiwan.
- Division of Gastroenterology and Hepatology, E-Da Cancer Hospital, Kaohsiung, Taiwan.
- Chang Gung University, Chang Gung Memorial Hospital, Linkou Branch, Taiwan.
- The Alfred Hospital and Monash University, Melbourne, Victoria, Australia.
- Gilead Sciences, Inc., Foster City, California, USA.
ORCID-Profile: Edward J Gane, Cheng-Hao Tseng, Chun-Yen Lin, Wan-Long Chuang, Kosh Agarwal
Förderung
- Gilead Sciences
Zitieren
APA
Gane, E. J., Chen, C. Y., Tseng, C. H., Lin, C. Y., Roberts, S. K., Tedesco, D., Abramov, F., Zhang, F., Odegard, J. M., Wallin, J. J., Shaik, N. A., Chew, T., Lad, L., Wang, A. Y., Balsitis, S., Fletcher, S. P., Lau, A. H., Chuang, W. L., & Agarwal, K. (2026). Safety, Tolerability, and Pharmacodynamics of GS ‐4224 in Healthy Participants and Participants With Chronic Hepatitis B. Liver International, 46(6). https://doi.org/10.1111/liv.70695
Vancouver
Gane EJ, Chen CY, Tseng CH, Lin CY, Roberts SK, Tedesco D, et al. Safety, Tolerability, and Pharmacodynamics of GS ‐4224 in Healthy Participants and Participants With Chronic Hepatitis B. Liver International. 2026;46(6). doi:10.1111/liv.70695
BibTeX
@article{Gane2026,
author = {Gane, Edward J and Chen, Chi-Yi and Tseng, Cheng-Hao and Lin, Chun-Yen and Roberts, Stuart K and Tedesco, Dana and Abramov, Frida and Zhang, Fangqiu and Odegard, Jared M and Wallin, Jeffrey J and Shaik, Naveed A and Chew, Teri and Lad, Latesh and Wang, Adele Y and Balsitis, Scott and Fletcher, Simon P and Lau, Audrey H and Chuang, Wan-Long and Agarwal, Kosh},
title = {Safety, Tolerability, and Pharmacodynamics of GS ‐4224 in Healthy Participants and Participants With Chronic Hepatitis B},
journal = {Liver International},
year = {2026},
volume = {46},
number = {6},
doi = {10.1111/liv.70695}
}
EUVIMED